Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 29, 2015 11:43 PM ET

Biotechnology

Company Overview of Ardelyx, Inc.

Company Overview

Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic small molecule therapeutics for the gastrointestinal (GI) tract to treat cardio-renal, GI, and metabolic diseases. Its lead product candidate is tenapanor, a small molecule NHE3 inhibitor, which has completed Phase 2b clinical trial for the treatment of patients with constipation-predominant irritable bowel syndrome and hyperphosphatemic patients with chronic kidney disease on dialysis, as well as Phase 2a clinical trial in patients with late-stage chronic kidney disease. The company’s discovery and lead development programs that are in research phase include RDX002 NaP2b inhibitor for hyperphosphatemia; RDX009 TGR5 ago...

34175 Ardenwood Boulevard

Suite 100

Fremont, CA 94555

United States

Founded in 2007

34 Employees

Phone:

510-745-1700

Fax:

510-745-0493

Key Executives for Ardelyx, Inc.

Chief Executive Officer, President and Director
Age: 50
Total Annual Compensation: $466.0K
Chief Financial Officer
Age: 47
Total Annual Compensation: $318.9K
Senior Vice President of Drug Development
Age: 54
Total Annual Compensation: $277.5K
Chief Scientific Officer and Executive Vice President
Age: 46
Total Annual Compensation: $132.1K
Compensation as of Fiscal Year 2014.

Ardelyx, Inc. Key Developments

Ardelyx, Inc. Announces Unaudited Earnings Results for Second Quarter and Six Months Ended June 30, 2015

Ardelyx, Inc. announced unaudited earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $18,143,000, income from operations of $9,056,000 and net income and comprehensive income of $9,007,000 or $0.42 per diluted share compared to the total revenue of $9,137,000, income from operations of $2,751,000 and net loss and comprehensive income of $3,753,000 or $0.18 per diluted share for the same quarter a year ago. For the six months period, the company reported total revenue of $24,026,000, income from operations of $5,566,000, and net income and comprehensive income of $5,505,000 or $0.27 per diluted share compared to the total revenue of $17,687,000, income from operations of $2,287,000, and net income and comprehensive income of $682,000 for the same period a year ago.

Ardelyx, Inc., Q2 2015 Earnings Call, Aug 12, 2015

Ardelyx, Inc., Q2 2015 Earnings Call, Aug 12, 2015

Ardelyx, Inc. to Report Q2, 2015 Results on Aug 12, 2015

Ardelyx, Inc. announced that they will report Q2, 2015 results at 8:15 PM, GMT Standard Time on Aug 12, 2015

Similar Private Companies By Industry

Company Name Region
Novo Biosciences, Inc. United States
Insight Genetics, Inc. United States
Medisyn Technologies, Inc. United States
BioControl Systems, Inc. United States
FermaVir Pharmaceuticals, L.L.C. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
June 2, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ardelyx, Inc., please visit www.ardelyx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.